Radius Health, Inc. (RDUS)
Largest Insider Buys in Sector
RDUS Stock Price History Chart
RDUS Stock Performance
About Radius Health, Inc.
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant …
Insider Activity of Radius Health, Inc.
Over the last 12 months, insiders at Radius Health, Inc. have bought $0 and sold $519,462 worth of Radius Health, Inc. stock.
On average, over the past 5 years, insiders at Radius Health, Inc. have bought $17.42M and sold $243,448 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,682,966 shares for transaction amount of $16.95M was made by Rosen David Efraim () on 2022‑08‑10.
List of Insider Buy and Sell Transactions, Radius Health, Inc.
| 2024-11-07 | Sale | SVP & President, Recycling P&S | 9,000 0.0318% | $19.52 | $175,680 | -2.75% | ||
| 2024-11-05 | Sale | SVP, GC, CCO, Corp. Secretary | 1,379 0.0042% | $16.63 | $22,933 | +14.81% | ||
| 2024-10-30 | Sale | SVP & President, Recycling P&S | 17,675 0.0547% | $17.08 | $301,889 | +12.59% | ||
| 2024-05-06 | Sale | SVP, CFO | 1,021 0.0034% | $18.57 | $18,960 | -8.09% | ||
| 2022-08-10 | 1.68M 3.0714% | $10.07 | $16.95M | -10.87% | ||||
| 2022-05-18 | 10 percent owner | 477,824 0.4823% | $5.57 | $2.66M | -11.81% | |||
| 2022-05-18 | 477,824 0.4823% | $5.57 | $2.66M | -11.81% | ||||
| 2022-01-06 | 10 percent owner | 300,000 0.3433% | $6.31 | $1.89M | -22.30% | |||
| 2022-01-05 | 10 percent owner | 250,000 0.2854% | $6.30 | $1.57M | -32.62% | |||
| 2021-12-16 | 10 percent owner | 146,685 0.1881% | $7.07 | $1.04M | -24.46% | |||
| 2021-12-15 | 10 percent owner | 180,744 0.2218% | $6.77 | $1.22M | -23.29% | |||
| 2021-12-14 | 10 percent owner | 94,103 0.1162% | $6.81 | $640,936 | -23.50% | |||
| 2021-12-13 | 10 percent owner | 187,391 0.2405% | $7.08 | $1.33M | -22.89% | |||
| 2021-12-10 | 10 percent owner | 768,171 0.9989% | $7.17 | $5.51M | -23.67% | |||
| 2021-12-09 | 10 percent owner | 264,644 0.3637% | $7.58 | $2.01M | -23.48% | |||
| 2021-12-08 | 10 percent owner | 560,691 0.815% | $8.02 | $4.5M | -24.86% | |||
| 2021-09-29 | 10 percent owner | 100,000 0.2346% | $12.95 | $1.29M | +0.23% | |||
| 2021-09-22 | 10 percent owner | 150,000 0.3337% | $12.28 | $1.84M | +6.78% | |||
| 2021-03-05 | Sale | Principal Finance Accounting | 370 0.0014% | $20.88 | $7,726 | +26.41% | ||
| 2021-02-25 | Sale | Chief Commercial Officer | 1,322 0.0045% | $18.93 | $25,025 | +36.10% |
Insider Historical Profitability
| BB BIOTECH AG | 8733538 31.2411% | $15.52 | 1 | 0 | <0.0001% | |
| BIOTECH TARGET N V | 10 percent owner | 8733538 31.2411% | $15.52 | 10 | 0 | +39.72% |
| Rosen David Efraim | 8642271 30.9146% | $15.52 | 1 | 0 | <0.0001% | |
| Rubric Capital Management LP | 10 percent owner | 6959305 24.8944% | $15.52 | 7 | 0 | <0.0001% |
| BIOTECH GROWTH N V | 10 percent owner | 6881685 24.6167% | $15.52 | 55 | 0 | +14.83% |